An Observational Study on Patients With Rheumatoid Arthritis Treated With MabThera (Rituximab)

Hoffmann-La Roche151 enrolled

Overview

This observational study will assess the execution, efficacy and safety of treatment with MabThera in patients with rheumatoid arthritis. Data from patients receiving MabThera according to local treatment guidelines will be collected for 29 months. Target sample size is 100-200 patients.

Study Type

OBSERVATIONAL

Enrollment

151

Conditions

Rheumatoid Arthritis

Interventions

rituximab [Mabthera/Rituxan]DRUG

As prescribed by physician

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * adult patients, \>/= 18 years of age * rheumatoid arthritis * treatment with rituximab Exclusion Criteria: * unable/unwilling to give informed consent to data collection

Locations (8)

Unnamed facility

Hämeenlinna, Finland

Unnamed facility

Helsinki, Finland

Unnamed facility

Joensuu, Finland

Unnamed facility

Jyväskylä, Finland

Outcomes

Primary Outcomes

Efficacy: DAS28

Time frame: 29 months

Secondary Outcomes

Efficacy: TJC, SJC, ESR, HAQ, CRP, patient's assessment (VAS)

Time frame: 29 months

Safety: serious and non-serious adverse events

Time frame: 29 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.